DelMar Pharmaceuticals to Participate in Key Opinion Leader Luncheon on Glioblastoma Multiforme Featuring Dr. James Perry, MD Mar 2, 2017
DelMar Pharmaceuticals Announces Dosing of the First Patient in Phase Two Clinical Trial of VAL-083 for MGMT-unmethylated Recurrent Glioblastoma Multiforme (GBM) Feb 13, 2017
DelMar Pharmaceuticals and MD Anderson Initiate New Phase Two Clinical Trial of VAL-083 for MGMT-unmethylated Recurrent Glioblastoma Multiforme (GBM) Jan 25, 2017
DelMar Pharmaceuticals Receives Additional Non-Dilutive Funding from the Government of Canada to Support Expanded Research with Lead Product Candidate VAL-083 Jan 9, 2017
DelMar Pharmaceuticals Receives Notice of Allowance from the US Patent and Trademark Office for Key Patent for VAL-083 Dec 14, 2016
DelMar Pharmaceuticals Delivers an Address and Presents an Overview of Upcoming GBM Trials with VAL-083 at the CNS Anticancer Drug Discovery Development Conference and Society for NeuroOncology Annual Meeting Nov 21, 2016
DelMar Pharmaceuticals Announces First Quarter Fiscal Year 2017 Financial Results and Corporate Update Nov 14, 2016
DelMar Pharmaceuticals Presents New VAL-083 Data at Two International Scientific Conferences Nov 7, 2016
DelMar Pharmaceuticals Presents Overview of VAL-083's Unique Anticancer Mechanism at the European Association of Neuro-Oncology (EANO) Annual Meeting Oct 17, 2016
